Marilyn Rynders v. E.I. Du Pont, De Nemours & Company, a Delaware Corporation. James W. Buhler v. E.I. Du Pont, De Nemours & Company, a Delaware Corporation.

21 F.3d 835, 23 U.C.C. Rep. Serv. 2d (West) 333, 1994 U.S. App. LEXIS 7420
CourtCourt of Appeals for the Eighth Circuit
DecidedApril 15, 1994
Docket93-1643
StatusPublished
Cited by1 cases

This text of 21 F.3d 835 (Marilyn Rynders v. E.I. Du Pont, De Nemours & Company, a Delaware Corporation. James W. Buhler v. E.I. Du Pont, De Nemours & Company, a Delaware Corporation.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Marilyn Rynders v. E.I. Du Pont, De Nemours & Company, a Delaware Corporation. James W. Buhler v. E.I. Du Pont, De Nemours & Company, a Delaware Corporation., 21 F.3d 835, 23 U.C.C. Rep. Serv. 2d (West) 333, 1994 U.S. App. LEXIS 7420 (8th Cir. 1994).

Opinion

21 F.3d 835

62 USLW 2756, 23 UCC Rep.Serv.2d 333,
Prod.Liab.Rep.(CCH)P. 13,832

Marilyn RYNDERS, Appellant,
v.
E.I. DU PONT, DE NEMOURS & COMPANY, a Delaware corporation.
Appellee.
James W. BUHLER, Appellant,
v.
E.I. DU PONT, DE NEMOURS & COMPANY, a Delaware corporation. Appellee.

No. 93-1643.

United States Court of Appeals,
Eighth Circuit.

Submitted Nov. 11, 1993.
Decided April 15, 1994.

Barry G. Reed, Minneapolis, MN, argued (Ronald S. Goldser, Minneapolis, MN, Jeffrey Viken, Rapid City, SD, David Strait, Watertown, SD, on the brief), for appellant.

Edward M. Mansfield of Phoenix, AZ, argued (Ross F. Schmucki, Barry Fish, and Michale O. Miller, Phoenix William Porter and Patricia Meyers, Rapid City, SD, on the brief), for appellee.

Before RICHARD S. ARNOLD, Chief Judge, BEAM, Circuit Judge, and JACKSON*, District Judge.

BEAM, Circuit Judge.

Marilyn Rynders and James Buhler brought this diversity products liability action against E.I. Du Pont, De Nemours & Company (DuPont), the manufacturer of certain polymers commonly known by their trade name, Teflon. Vitek, Inc. (Vitek), a now bankrupt medical supplies manufacturer, used Teflon to construct the cartilage replacement implants that injured both Rynders and Buhler. After a hearing, the district court1 entered judgment as a matter of law dismissing all implied warranty claims and the jury returned a verdict for DuPont on strict liability and negligence claims. Rynders and Buhler appeal arguing that the verdicts and the court's judgment resulted from several misinterpretations of South Dakota law.2 We affirm.

I. BACKGROUND

Dr. Charles Homsy, a former DuPont research engineer, invented Proplast--a semisoft, porous, spongy material--while doing prosthesis research at Methodist Hospital in Houston, Texas, in 1968. Homsy manufactured Proplast by combining polytetrafluoroethylene (PTFE Teflon), purchased from DuPont, with carbon, solvents and other ingredients. He employed a process of heating, compressing and drying this mixture to produce the semisoft Proplast material from the base ingredients. Homsy founded Vitek in 1969 to manufacture and distribute his Proplast prosthetic devices while he continued his research at Methodist Hospital. Vitek patented Proplast in 1976.

One of the devices Vitek sold was the Proplast Interpositional Implant designed to correct temporomandibular joint (TMJ) disorders. Vitek constructed the implant by molding Proplast into the required shape and laminating it with fluorinated ethylene propylene (FEP), a slippery polymer film, to protect the Proplast from wear in load-bearing joints such as the TMJ.3 The FDA authorized the sale of Proplast TMJ implants in 1983. Rynders and Buhler both had Proplast implants surgically placed in their jaws by oral surgeons to correct TMJ disorders.

When Homsy first sought to purchase Teflon from DuPont for his prosthesis research, DuPont advised the purchasing agent of Methodist Hospital through a March 13, 1967, letter that Teflon was an "industrial material" that was "not made for medical use." Appellants' App. at A-201. DuPont's letter also noted several past scientific studies indicating that PTFE implants wore badly and disintegrated in load-bearing joints, releasing PTFE particles into the body of the subject. These studies concluded that abraded PTFE particles from early prosthesis experiments caused severe foreign body giant cell reactions, resulting in granulomatous tissue and significant bone erosion. DuPont warned that its Teflon products are not tested for medical uses and stated that the Hospital must rely on its own judgment as to the material's safety. Finally, DuPont required the Hospital to execute a disclaimer accepting full responsibility for the consequences of its proposed use of Teflon.

Homsy responded to DuPont with a letter stating that his own research and more recent scientific studies had uncovered solutions to the problems with earlier PTFE implants. Id. at A-203-04. Homsy's letter also accepted all responsibility for testing PTFE Teflon for use in prostheses. Based on Homsy's letter and the Hospital's execution of the disclaimer, DuPont filled Methodist Hospital's order for Teflon.

DuPont again advised Vitek that it did not market surgical grades of Teflon in response to Vitek's request in 1977 for assistance in getting Food and Drug Administration (FDA) approval for Proplast. Id. at A-119-22. DuPont required Homsy, the president of Vitek, to sign a "Statement of Policy" declaring that he would conduct any clinical tests on humans in accordance with the Federal Food, Drug and Cosmetic Act. Id. at A-122. Homsy's research included correspondence with one of the scientists who had identified the previous PTFE implant problems, a review of the scientific literature on PTFE, and years of clinical studies with Proplast implants in animals and in humans. All of his experiences led Homsy to believe that Proplast was an "excellent implant material." Appellee's App. at 11. Indeed, the FDA advisory committee stated that "the safety and effectiveness of the material [Proplast] has been established through long-term clinical trials." 47 Fed.Reg. 2810, 2818 (1982). Unfortunately, the accolades for Proplast were premature.

An oral surgeon placed Proplast implants in both of Rynders' TMJs on October 23, 1985, to correct TMJ displacement problems that had caused Rynders chronic jaw pain and headaches. Rynders had the Proplast implants removed on January 6, 1988, at the recommendation of her oral surgeon, because she continued to suffer from TMJ problems. Upon removal, the surgeon observed that the implants were fractured and that the bony surfaces of Rynder's TMJs had eroded since the implantation operation. Transcript at 167-68. The surgeon further noted granulomatous tissue which he concluded was probably a foreign body reaction to the implants. Id. at 168. Rynders has subsequently undergone numerous surgical procedures in order to partially reconstruct her TMJs with bone fragments from her ribs and from her left hip. She continues to suffer from the deterioration of her jaw.

Buhler had Proplast devices implanted in both TMJs on June 14, 1984, to relieve pain, his inability to fully open his mouth, and clicking noises in his jaw that he experienced after an automobile accident. Although Buhler was asymptomatic after his surgery, his oral surgeon warned him on September 6, 1990, of evidence that the implants might cause bone resorption and that this problem may not manifest itself in outward symptoms. Subsequent tests revealed that Buhler had suffered bone deterioration in his TMJs and also revealed granulomatous formations. Transcript at 558-60. When Buhler's implants were removed on December 6, 1990, the surgeon noted that they were worn and fragmented. Buhler has since undergone numerous surgical procedures to correct his TMJ problems and he continues to suffer physical symptoms and emotional anguish as a result of the failure of the Proplast implants.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hoyt v. Vitek, Inc.
894 P.2d 1225 (Court of Appeals of Oregon, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
21 F.3d 835, 23 U.C.C. Rep. Serv. 2d (West) 333, 1994 U.S. App. LEXIS 7420, Counsel Stack Legal Research, https://law.counselstack.com/opinion/marilyn-rynders-v-ei-du-pont-de-nemours-company-a-delaware-ca8-1994.